Get the Stockscreener App
33.57
0.03%
-0.010
Pre-market:
33.57
Omnicell Inc stock is traded at $33.57, with a volume of 891.75K.
It is down -0.03% in the last 24 hours and up +10.25% over the past month.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
See More
Previous Close:
$33.58
Open:
$33.72
24h Volume:
891.75K
Relative Volume:
1.81
Market Cap:
$1.54B
Revenue:
$1.15B
Net Income/Loss:
$23.09M
P/E Ratio:
67.14
EPS:
0.5
Net Cash Flow:
$89.18M
1W Performance:
+7.94%
1M Performance:
+10.25%
6M Performance:
+7.39%
1Y Performance:
-30.98%
1-Day Range:
$32.73
$34.36
1-Week Range:
$29.09
$34.36
52-Week Range:
$22.66
$53.31
Omnicell Inc Stock (OMCL) Company Profile
Name
Omnicell Inc
Sector
Industry
Phone
(877) 415-9990
Address
4220 NORTH FREEWAY, FORT WORTH
Compare OMCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
33.57 | 1.54B | 1.15B | 23.09M | 89.18M | 0.50 |
|
VEEV
Veeva Systems Inc
|
291.20 | 46.72B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
89.85 | 14.99B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
66.00 | 12.33B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
94.58 | 8.01B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.85 | 7.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-03-24 | Initiated | Barclays | Underweight |
| Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Sep-26-23 | Reiterated | Wells Fargo | Underweight |
| Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
| Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-09-22 | Initiated | BofA Securities | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
| Dec-06-21 | Resumed | Wells Fargo | Overweight |
| Jun-09-21 | Initiated | JP Morgan | Neutral |
| May-24-21 | Initiated | BTIG Research | Buy |
| Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-20 | Initiated | Berenberg | Buy |
| Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Feb-07-20 | Reiterated | Dougherty & Company | Buy |
| Nov-21-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-07-19 | Reiterated | Dougherty & Company | Buy |
| Jun-29-18 | Resumed | The Benchmark Company | Buy |
| Sep-05-17 | Reiterated | The Benchmark Company | Buy |
| Jul-28-17 | Reiterated | Dougherty & Company | Buy |
| Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-19-17 | Initiated | Dougherty & Company | Buy |
| Dec-06-16 | Reiterated | The Benchmark Company | Buy |
| Jul-07-16 | Reiterated | FBR Capital | Outperform |
| Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
| Jan-07-16 | Initiated | The Benchmark Company | Buy |
| Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
| Oct-30-15 | Reiterated | FBR Capital | Outperform |
| Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
| Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell Inc Stock (OMCL) Latest News
Strs Ohio Sells 18,800 Shares of Omnicell, Inc. $OMCL - MarketBeat
Will Omnicell Inc. (OC9) stock deliver compounding returns2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
What Wall Street predicts for Omnicell Inc. stock priceTake Profit & Verified Momentum Watchlists - newser.com
Automated trading signals detected on Omnicell Inc.Trade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
How Omnicell Inc. (OC9) stock reacts to new regulationsJuly 2025 Pullbacks & Verified Chart Pattern Signals - newser.com
Is Omnicell Inc. stock a safe buy before earnings2025 Top Decliners & Smart Swing Trading Techniques - newser.com
How Omnicell Inc. stock performs in stagflationTrade Volume Report & Low Risk High Win Rate Stock Picks - newser.com
Pier Capital LLC Raises Stock Holdings in Omnicell, Inc. $OMCL - MarketBeat
Why Omnicell Inc. stock could outperform in 2025Portfolio Update Report & Stepwise Trade Signal Guides - newser.com
Using data filters to optimize entry into Omnicell Inc.Earnings Growth Summary & Verified Short-Term Plans - newser.com
Omnicell, Inc. (NASDAQ:OMCL) Q3 2025 Earnings Call Transcript - Insider Monkey
Omnicell (OMCL) Is Up 7.9% After Q3 Beat and Outlook Raise Is the Growth Story Gaining Momentum? - Yahoo Finance
Omnicell’s Earnings Call: Growth Amid Challenges - The Globe and Mail
Omnicell (NASDAQ:OMCL) Announces Quarterly Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Omnicell (NASDAQ:OMCL) Price Target Raised to $45.00 - MarketBeat
Omnicell (NASDAQ:OMCL) Shares Gap UpStill a Buy? - MarketBeat
Omnicell (OMCL): Benchmark Raises Price Target to $45.00, Mainta - GuruFocus
Omnicell, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape - Markets Mojo
Omnicell Q3 2025 slides: Medication management leader beats estimates, accelerates SaaS growth - Investing.com Australia
Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance - MarketBeat
Omnicell (NASDAQ:OMCL) Issues Q4 2025 Earnings Guidance - MarketBeat
Will Omnicell Inc. outperform the market2025 Short Interest & Free Growth Oriented Trading Recommendations - newser.com
Central Fill Pharmacy Automation Market Projections - openPR.com
Will Omnicell Inc. stock maintain dividend yieldJuly 2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
Omnicell Surpasses Q3 2025 Financial Expectations - TipRanks
Omnicell (OMCL): Return to Profitability Reinforces Bullish Narrative as Margins and Earnings Forecasts Improve - Sahm
Omnicell: Q3 Earnings Snapshot - CT Insider
Why Omnicell Stock Crushed the Market Today - The Motley Fool
Omnicell Inc (OMCL) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges - Investing.com Canada
Omnicell Inc (OMCL) Q3 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Omnicell Q3 2025 Earnings: Revenue & Profit Beat Estimates, Stock JumpsNews and Statistics - IndexBox
Why Omnicell (OMCL) Stock Is Trading Up Today - TradingView
Tranche Update on Omnicell, Inc.'s Equity Buyback Plan announced on May 22, 2025. - MarketScreener
Omnicell Q3 2025 slides: Medication management leader beats estimates, accelerates SaaS growth By Investing.com - Investing.com South Africa
Omnicell shares climb 4% after strong Q3 beat and raised 2025 outlook - MSN
Omnicell (OMCL) Shares Cross Above 200 DMA - Nasdaq
Earnings call transcript: Omnicell’s Q3 2025 earnings beat expectations, stock surges - Investing.com
Omnicell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Omnicell Inc Stock (OMCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):